series	seriesDescription	geoAreaCode	geoAreaName	value	time_detail	upperBound	lowerBound	basePeriod	source	footnotes	nature_code	nature_desc	units_code	units_desc	reportingType_code	reportingType_desc	timePeriod	value_detail	lowerBound_detail	upperBound_detail	level	parentCode	parentName	type	X	Y	ISO3	UN_Member	Country_Profile
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	1	World	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	100	Bulgaria	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	151	Eastern Europe	Country	25.23763153	42.75731323	BGR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	Myanmar	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	35	South-Eastern Asia	Country	96.51752295	21.19332882	MMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	104	Myanmar	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	35	South-Eastern Asia	Country	96.51752295	21.19332882	MMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	108	Burundi	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	29.89080992	-3.366387428	BDI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	11	Western Africa	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	Cambodia	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	35	South-Eastern Asia	Country	104.922836	12.71163737	KHM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	Cambodia	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	35	South-Eastern Asia	Country	104.922836	12.71163737	KHM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	116	Cambodia	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	35	South-Eastern Asia	Country	104.922836	12.71163737	KHM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	Algeria	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	15	Northern Africa	Country	2.678164227	28.15940032	DZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	12	Algeria	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	15	Northern Africa	Country	2.678164227	28.15940032	DZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	120	Cameroon	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	17	Middle Africa	Country	12.7419827	5.692387031	CMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	124	Canada	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	21	Northern America	Country	-101.6575058	57.72360191	CAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	13	Central America	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	135	Caucasus and Central Asia	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	15.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	14	Eastern Africa	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	140	Central African Republic	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	17	Middle Africa	Country	20.93559492	7.003720791	CAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	142	Asia	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	143	Central Asia	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	145	Western Asia	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	15	Northern Africa	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	150	Europe	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	151	Eastern Europe	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	152	Chile	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-71.23029019	-35.2652885	CHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	154	Northern Europe	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	155	Western Europe	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	17	Middle Africa	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	170	Colombia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-73.07446751	3.888209046	COL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	178	Congo	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	15.22052612	-0.840544119	COG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	18	Southern Africa	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	202	Sub-Saharan Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	31.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	180	Democratic Republic of the Congo	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	17	Middle Africa	Country	23.65496507	-2.877154732	COD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	188	Costa Rica	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	13	Central America	Country	-84.19712782	9.970998683	CRI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	28.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	51.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	19	Americas	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	Cyprus	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	33.22285964	35.05659437	CYP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	Cyprus	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	33.22285964	35.05659437	CYP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	196	Cyprus	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	33.22285964	35.05659437	CYP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	199	Least Developed Countries (LDC)	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	19.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	47.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	2	Africa	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	20	Andorra	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	39	Southern Europe	Country	1.576257417	42.54548611	AND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	21.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	202	Sub-Saharan Africa	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	2	Africa	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	204	Benin	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	2.339933594	9.65401646	BEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	208	Denmark	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	9.326571283	56.03829721	DNK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	21	Northern America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	27.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	214	Dominican Republic	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	29	Caribbean	Country	-70.49847576	18.89832088	DOM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	218	Ecuador	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-78.37005241	-1.447785891	ECU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	222	El Salvador	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	13	Central America	Country	-88.86862995	13.73603564	SLV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	231	Ethiopia	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	39.63505296	8.631223181	ETH	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	Eritrea	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	38.11074289	16.12894644	ERI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	232	Eritrea	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	38.11074289	16.12894644	ERI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	24	Angola	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	17	Middle Africa	Country	17.57817062	-12.33724746	AGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	242	Fiji	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	54	Melanesia	Country	177.9660884	-17.83301566	FJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	246	Finland	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	23.308447	61.91586738	FIN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	250	France	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	155	Western Europe	Country	2.457288129	46.62660861	FRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	262	Djibouti	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	42.18274707	11.56004161	DJI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	Georgia	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	43.3713615	42.04813028	GEO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	Georgia	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	43.3713615	42.04813028	GEO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	268	Georgia	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	43.3713615	42.04813028	GEO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	270	Gambia	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-15.39944785	13.45295927	GMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	275	State of Palestine	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	35.25694122	31.94347933	PSE	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	276	Germany	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	155	Western Europe	Country	10.3806066	51.08862743	DEU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	288	Ghana	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-1.205623522	7.964825185	GHA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	29	Caribbean	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	296	Kiribati	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	57	Micronesia	Country	-157.5643005	1.768837732	KIR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	30	Eastern Asia	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	300	Greece	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	39	Southern Europe	Country	22.58307827	39.47301873	GRC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	31	Azerbaijan	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	50.01064725	40.39229544	AZE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	32	Argentina	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-65.14563274	-35.19446255	ARG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	51.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	320	Guatemala	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	13	Central America	Country	-91.2312746	15.00273719	GTM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	328	Guyana	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-58.97322037	4.788012784	GUY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	34	Southern Asia	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	340	Honduras	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	13	Central America	Country	-86.59974381	14.82243161	HND	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	348	Hungary	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	151	Eastern Europe	Country	19.41221519	47.1651448	HUN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	35	South-Eastern Asia	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	142	Asia	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	352	Iceland	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	-19.02116966	64.79134763	ISL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	36	Australia	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	53	Australia and New Zealand	Country	134.3499412	-25.57717202	AUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	368	Iraq	33.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	43.76606267	33.05013795	IRQ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	372	Ireland	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	-7.121425272	53.25274054	IRL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	376	Israel	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	34.62277992	31.06164552	ISR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	380	Italy	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	39	Southern Europe	Country	12.57022427	42.79917282	ITA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	384	Cte d'Ivoire	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-5.552690016	7.62211586	CIV	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	39	Southern Europe	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	150	Europe	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	392	Japan	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	30	Eastern Asia	Country	139.2716103	36.6554539	JPN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	398	Kazakhstan	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	143	Central Asia	Country	66.65359159	48.01963494	KAZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	4	Afghanistan	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	34	Southern Asia	Country	66.02688198	33.83160199	AFG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	404	Kenya	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	37.86096816	0.534797278	KEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	Republic of Korea	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	30	Eastern Asia	Country	127.8610254	36.45201023	KOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	Republic of Korea	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	30	Eastern Asia	Country	127.8610254	36.45201023	KOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	410	Republic of Korea	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	30	Eastern Asia	Country	127.8610254	36.45201023	KOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	414	Kuwait	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	47.49305029	29.53949468	KWT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	417	Kyrgyzstan	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	143	Central Asia	Country	74.52324839	41.46204516	KGZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	418	Lao People's Democratic Republic	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	35	South-Eastern Asia	Country	101.9901968	20.27482773	LAO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	419	Latin America and the Caribbean	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	19	Americas	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	422	Lebanon	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	35.89391711	33.92152458	LBN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	Lesotho	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	18	Southern Africa	Country	28.25362195	-29.58041814	LSO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	Lesotho	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	18	Southern Africa	Country	28.25362195	-29.58041814	LSO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	426	Lesotho	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	18	Southern Africa	Country	28.25362195	-29.58041814	LSO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	428	Latvia	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	26.42461876	56.64196636	LVA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	430	Liberia	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-9.311879038	6.448381009	LBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	21.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	27.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	432	Landlocked developing countries (LLDCs)	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	39.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	434	Libya	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	15	Northern Africa	Country	18.0295985	27.04042819	LBY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	44	Bahamas	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	29	Caribbean	Country	-78.05111663	24.69546597	BHS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	Lithuania	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	23.90517807	55.33680309	LTU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	440	Lithuania	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	23.90517807	55.33680309	LTU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	442	Luxembourg	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	155	Western Europe	Country	6.092656563	49.77679538	LUX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	450	Madagascar	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	46.6982339	-19.38514785	MDG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	454	Malawi	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	33.4884625	-13.40819859	MWI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	466	Mali	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-3.522016039	17.35311254	MLI	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	478	Mauritania	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-10.33187259	20.26089546	MRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	48	Bahrain	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	50.5490754	26.04407747	BHR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	Mauritius	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	57.568022	-20.28581998	MUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	480	Mauritius	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	57.568022	-20.28581998	MUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	484	Mexico	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	13	Central America	Country	-102.5148166	23.93378032	MEX	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	485	Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	496	Mongolia	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	30	Eastern Asia	Country	103.0728057	46.83892054	MNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	28.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	498	Republic of Moldova	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	151	Eastern Europe	Country	28.4650624	47.20236795	MDA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	79.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	5	South America	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	419	Latin America and the Caribbean	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	Bangladesh	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	34	Southern Asia	Country	89.17660788	22.86961622	BGD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	Bangladesh	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	34	Southern Asia	Country	89.17660788	22.86961622	BGD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	50	Bangladesh	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	34	Southern Asia	Country	89.17660788	22.86961622	BGD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	504	Morocco	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	15	Northern Africa	Country	-6.281942841	31.8440131	MAR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	508	Mozambique	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	38.18479941	-14.27963886	MOZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	Armenia	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	44.93839317	40.29499741	ARM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	Armenia	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	44.93839317	40.29499741	ARM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	51	Armenia	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	44.93839317	40.29499741	ARM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	512	Oman	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	57.87743482	21.98805614	OMN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	59.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	513	Europe and Northern America	74.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	66.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	514	Developed Regions	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	15.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	28.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	39.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	515	Developing Regions	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	Namibia	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	18	Southern Africa	Country	17.21907885	-22.13817068	NAM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	Namibia	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	18	Southern Africa	Country	17.21907885	-22.13817068	NAM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	516	Namibia	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	18	Southern Africa	Country	17.21907885	-22.13817068	NAM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	2.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	518	Eastern Asia (excluding Japan)	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	52	Barbados	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	29	Caribbean	Country	-59.5346489	13.13648273	BRB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	Nepal	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	34	Southern Asia	Country	83.94678863	28.25866332	NPL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	Nepal	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	34	Southern Asia	Country	83.94678863	28.25866332	NPL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	524	Nepal	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	34	Southern Asia	Country	83.94678863	28.25866332	NPL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	528	Netherlands	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	155	Western Europe	Country	5.331480568	51.86728884	NLD	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	53	Australia and New Zealand	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	6.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	26.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	54	Melanesia	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	27.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	543	Oceania (exc. Australia and New Zealand)	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	554	New Zealand	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	53	Australia and New Zealand	Country	170.4755673	-43.98721568	NZL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	558	Nicaragua	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	13	Central America	Country	-85.03060315	12.84210839	NIC	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	56	Belgium	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	155	Western Europe	Country	4.660976456	50.64104975	BEL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	76.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	562	Niger	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	9.400167877	17.42143036	NER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	Nigeria	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	8.097363256	9.585789025	NGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	Nigeria	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	8.097363256	9.585789025	NGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	566	Nigeria	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	8.097363256	9.585789025	NGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	32.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	57	Micronesia	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	570	Niue	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	61	Polynesia	Country	-169.8601693	-19.05000475	NIU	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	578	Norway	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	11.47846389	61.34311134	NOR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	63.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	583	Micronesia (Federated States of)	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	57	Micronesia	Country	158.225216	6.880670092	FSM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	46.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	38.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	29.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	584	Marshall Islands	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	57	Micronesia	Country	171.0839119	7.110213497	MHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	18.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	585	Palau	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	57	Micronesia	Country	134.5733878	7.502307591	PLW	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	586	Pakistan	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	34	Southern Asia	Country	68.80479684	29.36491634	PAK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	48.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	591	Panama	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	13	Central America	Country	-81.26616623	8.450965746	PAN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	Papua New Guinea	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	54	Melanesia	Country	145.8587761	-6.756057077	PNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	Papua New Guinea	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	54	Melanesia	Country	145.8587761	-6.756057077	PNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	598	Papua New Guinea	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	54	Melanesia	Country	145.8587761	-6.756057077	PNG	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	600	Paraguay	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-60.54854225	-21.70216237	PRY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	85.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	604	Peru	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-71.82093277	-13.58939705	PER	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	608	Philippines	61.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	35	South-Eastern Asia	Country	120.8601418	14.16591706	PHL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	61	Polynesia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				3	9	Oceania	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	9.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	16.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	62	Central and Southern Asia	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	Portugal	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	39	Southern Europe	Country	-7.961599811	39.68509315	PRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	620	Portugal	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	39	Southern Europe	Country	-7.961599811	39.68509315	PRT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	Guinea-Bissau	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-14.40182514	12.11760394	GNB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	Guinea-Bissau	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-14.40182514	12.11760394	GNB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	624	Guinea-Bissau	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-14.40182514	12.11760394	GNB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	634	Qatar	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	51.19152467	25.28355379	QAT	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	Russian Federation	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	151	Eastern Europe	Country	99.01404926	61.61899849	RUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	643	Russian Federation	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	151	Eastern Europe	Country	99.01404926	61.61899849	RUS	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	646	Rwanda	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	29.92310194	-1.999842114	RWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	San Marino	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	39	Southern Europe	Country	12.46329038	43.93841766	SMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	674	San Marino	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	39	Southern Europe	Country	12.46329038	43.93841766	SMR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	678	Sao Tome and Principe	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	17	Middle Africa	Country	6.609772265	0.241554875	STP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	68	Bolivia (Plurinational State of)	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-64.66224284	-16.71273412	BOL	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	682	Saudi Arabia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	44.54763347	24.12594211	SAU	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	686	Senegal	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-14.46636926	14.35920905	SEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	694	Sierra Leone	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-11.78306584	8.568604164	SLE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	22.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	40.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	78.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	702	Singapore	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	35	South-Eastern Asia	Country	103.8107883	1.361009155	SGP	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	703	Slovakia	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	151	Eastern Europe	Country	19.48495604	48.70741446	SVK	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	Slovenia	49.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	39	Southern Europe	Country	14.82209486	46.11958061	SVN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	Slovenia	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	39	Southern Europe	Country	14.82209486	46.11958061	SVN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	705	Slovenia	55.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	39	Southern Europe	Country	14.82209486	46.11958061	SVN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	70.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	710	South Africa	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	18	Southern Africa	Country	24.67184355	-29.99957544	ZAF	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	21.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	716	Zimbabwe	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	29.86909584	-19.00075492	ZWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	72.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	72	Botswana	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	18	Southern Africa	Country	23.81380223	-22.18810073	BWA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	5.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	8.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	23.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	722	Small island developing States (SIDS)	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	729	Sudan	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	15	Northern Africa	Country	29.95650159	16.02643066	SDN	0	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	3.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	12.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	20.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	51.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	738	Sub-Saharan Africa (inc. Sudan)	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	11.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	15.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	17.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	31.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	746	Northern Africa (exc. Sudan)	36.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				1			Group					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	1.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	19.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	19.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	30.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	35.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	44.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	45.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	52.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	747	Northern Africa and Western Asia	58.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	748	Eswatini	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	18	Southern Africa	Country	31.50149288	-26.56471011	SWZ	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	752	Sweden	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	14.3775338	60.60103109	SWE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	4.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	10.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	753	Eastern and South-Eastern Asia	14.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	13.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	25.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	37.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	50.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	62.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	756	Switzerland	83.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	155	Western Europe	Country	8.223158	46.96617097	CHE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	82.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	88.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	76	Brazil	84.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-53.08432878	-10.77668561	BRA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	34.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	86.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	768	Togo	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	0.97835765	8.532096072	TGO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	39.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	780	Trinidad and Tobago	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	29	Caribbean	Country	-61.29389504	10.41877263	TTO	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	784	United Arab Emirates	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	53.98279159	23.43322219	ARE	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	792	Turkey	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	35.42890329	38.9899684	TUR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	98.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	8	Albania	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	39	Southern Europe	Country	20.06660928	41.13897007	ALB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	60.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	64.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	800	Uganda	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	32.39100438	1.279557331	UGA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	89.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	826	United Kingdom of Great Britain and Northern Ireland	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	154	Northern Europe	Country	-2.23830539	53.27691757	GBR	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	80.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	96.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	834	United Republic of Tanzania	97.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	34.80521182	-6.265332606	TZA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	840	United States of America	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	21	Northern America	Country	-99.13830311	39.5277871	USA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	854	Burkina Faso	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	11	Western Africa	Country	-1.742843829	12.27491081	BFA	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	91.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	92.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	93.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	95.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	858	Uruguay	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-56.01387025	-32.8002838	URY	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	Uzbekistan	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	143	Central Asia	Country	63.11944558	41.77560518	UZB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	860	Uzbekistan	99.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	143	Central Asia	Country	63.11944558	41.77560518	UZB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	Venezuela (Bolivarian Republic of)	24.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	5	South America	Country	-66.15642084	7.121324748	VEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	Venezuela (Bolivarian Republic of)	7.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	5	South America	Country	-66.15642084	7.121324748	VEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	862	Venezuela (Bolivarian Republic of)	0.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	5	South America	Country	-66.15642084	7.121324748	VEN	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	41.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	73.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	69.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	71.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	887	Yemen	68.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	145	Western Asia	Country	45.22389143	15.22242099	YEM	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	77.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	90.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	894	Zambia	94.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				5	14	Eastern Africa	Country	27.850329	-14.59701056	ZMB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	43.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2008				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2009				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	53.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2010				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2011				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	54.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2012				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	56.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2013				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	57.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2014				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	65.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	67.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	9	Oceania	75.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				2	1	World	Region					
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	Solomon Islands	42.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2015				4	54	Melanesia	Country	160.1584117	-9.622391719	SLB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	Solomon Islands	87.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2016				4	54	Melanesia	Country	160.1584117	-9.622391719	SLB	1	1
SH_ACS_PCV3	Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)	90	Solomon Islands	81.0					WHO/UNICEF coverage estimates 2017 revision, July 2018		E	Estimated data	PT	Percentage	G	Global	2017				4	54	Melanesia	Country	160.1584117	-9.622391719	SLB	1	1
